KSK64

KSK64 is an investigational **small-molecule hydroxamic acid-type histone deacetylase inhibitor** reported as a **class II HDAC inhibitor**. Preclinical literature describes it as an epigenetic modulator with antitumor activity in **neuroblastoma** models, where it showed greater cytotoxicity in tumor cells than vorinostat with a potentially improved therapeutic window in non-malignant cells. It has also been studied as an anti-infective research compound for **Acanthamoeba keratitis**, where it demonstrated amoebicidal activity against trophozoites and inhibition of encystation. No brand name, regulatory approval, or clearly attributable commercial developer/manufacturer could be confirmed from the provided context.